Ginkgo Bioworks Holdings, Inc.
DNANYSEHealthcare● Active
$8.17
$-0.05(-0.61%)
Market Cap$533701132
P/E Ratio—
52W High$17.58
52W Low$5.37
Ginkgo Bioworks Holdings, Inc. (DNA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DNA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.17B | $0.23B | $0.25B | $0.48B | $0.31B |
| Cost of Revenue | $0.03B | $0.04B | $0.05B | $0.20B | $0.13B |
| Gross Profit | $0.14B | $0.19B | $0.20B | $0.27B | $0.18B |
| Gross Margin %(computed) | 81.48% | 83.02% | 78.52% | 57.25% | 58.68% |
| Operating Expenses | |||||
| R&D Expenses | $0.24B | $0.42B | $0.58B | $1.05B | $1.15B |
| G&A Expenses | $0.18B | $0.25B | $0.39B | $1.43B | $0.86B |
| Total Operating Expenses | $0.45B | $0.75B | $1.06B | $2.48B | $2.01B |
| Operating Income | ($0.32B) | ($0.56B) | ($0.86B) | ($2.21B) | ($1.83B) |
| Operating Margin %(computed) | -185.29% | -246.54% | -343.76% | -462.41% | -582.62% |
| Interest Income | $0.02B | $0.04B | $0.06B | $0.02B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.31B) | ($0.55B) | ($0.89B) | ($2.12B) | ($1.84B) |
| Income Tax Expense | ($0.00B) | ($0.00B) | ($0.00B) | ($0.02B) | ($0.00B) |
| Net Income | ($0.31B) | ($0.55B) | ($0.89B) | ($2.10B) | ($1.83B) |
| Net Margin %(computed) | -183.81% | -240.94% | -355.08% | -440.63% | -583.12% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.64 | $-10.54 | $-18.37 | $-50.15 | $-53.83 |
| Wtd Avg Shares | 0.06B | 0.05B | 0.05B | 0.04B | 0.03B |
| EBITDA | ($0.25B) | ($0.48B) | ($0.82B) | ($2.06B) | ($1.81B) |
| EBITDA Margin %(computed) | -149.63% | -213.35% | -326.62% | -431.16% | -575.67% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Ginkgo Bioworks Holdings, Inc. data
About Ginkgo Bioworks Holdings, Inc. (DNA) Income Statement
Ginkgo Bioworks Holdings, Inc. (DNA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, DNA reported revenue of $0.17B, gross profit of $0.14B (gross margin 81.48%), and net income of ($0.31B) — a net profit margin of -183.81%.
Frequently asked questions
DNA · 4 questionsGinkgo Bioworks Holdings, Inc. (DNA) reported revenue of $0.17B for 2025, down 25.1% year-over-year.
DNA revenueDNA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08